Moncef Slaoui, the chairman of research and development at GlaxoSmithKline, recently touted the advanced and innovative nature of therapies in the company’s late-stage pipeline.
Slaoui discussed the highly innovative therapies in the company’s late-stage pipeline with more verve than some of the drugs under review that could hit the market even sooner. Slaoui referred to GSK’s late-stage cancer immunotherapy MAGE-A3 as one of the company’s breakthrough innovations, Dow Jones Newswires reports.
GSK advanced MAGE-A3 into separate Phase III trials for patients with non-small cell lung cancer and melanoma. The company anticipates initial results from one of the studies as early as late 2013.
Another drug Slaoui discussed was darapladib, an add-on LpPLA2 enzyme statin-blocker from Human Genome Sciences. GSK has 14 late-stage programs with results anticipated over the next couple years with six drugs under regulatory review.
Some of the other therapies under review for GSK, including the once-weekly GLP1 diabetes drug albiglutide, are not first-in-class and face competition from established drugs that are already on the market, according to Dow Jones Newswires.
One major impending review is Breo, a once-daily respiratory treatment that faces an FDA panel on March 7 and potential approval in May. The company is looking to sustain its respiratory business after patents for twice-daily Advair fizzle.
Breo is under the microscope to determine its effectiveness in comparison to other treatments for smoker’s cough, asthma and chronic obstructive pulmonary disease.